Clinuvel Pharmaceuticals Limited (ASX:CUV)
Australia · Delayed Price · Currency is AUD | Market Cap | 460.41M -13.0% |
| Revenue (ttm) | 96.30M +5.8% |
| Net Income | 32.54M -16.1% |
| EPS | 0.64 -16.3% |
| Shares Out | 50.43M |
| PE Ratio | 14.18 |
| Forward PE | 12.33 |
| Dividend | 0.05 (0.55%) |
| Ex-Dividend Date | Sep 4, 2025 |
| Volume | 48,878 |
| Open | 8.86 |
| Previous Close | 8.93 |
| Day's Range | 8.86 - 9.18 |
| 52-Week Range | 8.57 - 14.00 |
| Beta | 0.61 |
| Analysts | Strong Buy |
| Price Target | 22.91 (+150.93%) |
| Earnings Date | Jun 10, 2026 |
About John Keells Holdings
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a... [Read more]
Financial Performance
In fiscal year 2025, Clinuvel Pharmaceuticals's revenue was 95.02 million, an increase of 7.76% compared to the previous year's 88.18 million. Earnings were 36.17 million, an increase of 1.50%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for CUV stock is "Strong Buy." The 12-month stock price target is $22.91, which is an increase of 150.93% from the latest price.
News
CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo study EMA emphasised its “totality of evidence” approach central photographic review and validated disease as...
CLINUVEL: advancing peptides for photomedicine and vitiligo care at AAD 2026
MELBOURNE, Australia, April 15, 2026 (GLOBE NEWSWIRE) -- CLINUVEL's innovative photomedicine and vitiligo programs featured extensively at the recent American Academy of Dermatology (AAD) Annual Meeti...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2026
Revenue grew 4% year-over-year to a record high, with profitability maintained despite a 22% rise in expenses driven by R&D and expansion. Cash reserves reached AUD 233 million, supporting self-funded growth and upcoming catalysts like clinical trial readouts and Nasdaq listing.
Clinuvel Pharmaceuticals Quarterly report: H1 2026
Clinuvel Pharmaceuticals has published its H1 2026 quarterly earnings report on February 26, 2026.
Clinuvel Pharmaceuticals Slides: H1 2026
Clinuvel Pharmaceuticals has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 26, 2026.
CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies
EXECUTIVE SUMMARY VALLAURIX Research, Development & Innovation Centre to expand its existing facilities and capabilities core focus on accelerating development of liquid long-acting drug delivery plat...
Clinuvel Pharmaceuticals Slides: Investor Presentation
Clinuvel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
CLINUVEL to advance novel pharmaceutical formulations in preclinical program
Next generation sustained-release formulations for a variety of peptides Next generation sustained-release formulations for a variety of peptides
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2025
Reported ninth consecutive annual profit with 10% revenue growth to $105M and a 34% net margin. Cash reserves rose 22%, supporting robust R&D and expansion, while the EPP and vitiligo markets continue to grow. Major clinical and regulatory milestones are expected in the coming year.
Clinuvel Pharmaceuticals Annual report: H2 2025
Clinuvel Pharmaceuticals has published its H2 2025 annual report on August 28, 2025.
Clinuvel Pharmaceuticals Slides: H2 2025
Clinuvel Pharmaceuticals has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 28, 2025.
CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist
Executive summary plan to upgrade American Depository Receipt (ADR) program (CLVLY) to a Level II ADR listed on Nasdaq, expected before the end of 2025 CLINUVEL's primary listing on the ASX will remai...
Clinuvel Pharmaceuticals Slides: Investor Presentation
Clinuvel Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 24, 2025.
CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105
CLINUVEL has met its recruitment target in its phase III trial (CUV105) of SCENESSE® (afamelanotide 16mg) in vitiligo, with more than 200 patients enrolled
Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025
MELBOURNE, Australia, March 03, 2025 (GLOBE NEWSWIRE) -- World-leading photomedicine company CLINUVEL will make its début at the American Academy of Dermatology (AAD) Annual Meeting from March 7–11, w...
Clinuvel Pharmaceuticals Earnings Call Transcript: H1 2025
Half-year results showed strong revenue and profit growth, with robust cash reserves and continued expansion in key markets. Investment in late-stage clinical programs is set to rise, while a prudent capital management approach supports future growth and resilience.
Clinuvel Pharmaceuticals Quarterly report: H1 2025
Clinuvel Pharmaceuticals has published its H1 2025 quarterly earnings report on February 27, 2025.
Clinuvel Pharmaceuticals Slides: H1 2025
Clinuvel Pharmaceuticals has posted slides in relation to its H1 2025 quarterly earnings report, which was published on February 27, 2025.
Clinuvel Pharmaceuticals Transcript: AGM 2024
The meeting highlighted record financial results, board renewal, and strategic expansion into new therapies and photocosmetics. Key challenges include CEO succession, clinical trial completion, and leveraging strong cash reserves for growth.
Clinuvel Pharmaceuticals Slides: FY 2024
Clinuvel Pharmaceuticals has posted slides in relation to its FY 2024 quarterly earnings report, which was published on October 15, 2024.
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP
MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its novel photoprotective therapy SCENESSE® (afamelanotide...
Clinuvel Pharmaceuticals Earnings Call Transcript: H2 2024
Record revenue and profit were achieved, driven by Scenesse demand and expansion in key markets. Strong margins, robust cash reserves, and a debt-free balance sheet support ongoing R&D, new product launches, and a continued share buyback program.
Clinuvel Pharmaceuticals Annual report: H2 2024
Clinuvel Pharmaceuticals has published its H2 2024 annual report on August 29, 2024.
Clinuvel Pharmaceuticals Slides: H2 2024
Clinuvel Pharmaceuticals has posted slides in relation to its H2 2024 quarterly earnings report, which was published on August 29, 2024.
Afamelanotide in fair-skinned Parkinson's patients
MELBOURNE, Australia, June 18, 2024 (GLOBE NEWSWIRE) -- CLINUVEL today announced a novel clinical program evaluating afamelanotide as a treatment in early-stage Parkinson's Disease (PD or Parkinson's)...